SWOG clinical trial number
E1199

A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paciltaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High-Risk Node Negative Breast Cancer

Closed
Phase
Published
Abbreviated Title
ADJUVANT: Doxorubicin/cyclophosphamide -> paclitaxel or docetaxel
Activated
12/01/1999
Closed
01/08/2002
Participants
NCORP, Members, Medical Oncologists, Surgeons, Pathologists

Research committees

Breast Cancer

Treatment

Cyclophosphamide Paclitaxel Docetaxel Doxorubicin AC

Other Clinical Trials

CTSU-A012301
SWOG Clinical Trial Number
S2212
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Activated
07/21/2023
32% Accrual
Accrual
32%
Open
Phase